Immunofluorescence staining of VE‐cadherin in lung tissues demonstrated that the COPD + AS group had decreased expression of VE‐cadherin, while TXL–Ato combination treatment restored VE‐cadherin levels at cell–cell junctions (Figure 2d). This evidence concerns the gene TXNL1 and chronic obstructive pulmonary disease.